Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Karen Howe"'
Publikováno v:
Cancer Research. 75:P4-07
HER2 positive breast cancer accounts for approximately 20-25 % of breast cancers. Trastuzumab, a humanised monoclonal antibody, is approved for the treatment of HER2 positive breast cancer. However, the majority of metastatic HER2 positive breast can
Autor:
Julie, Errington, Ghada, Malik, Julie, Evans, Jenny, Baston, Annie, Parry, Lisa, Price, Hina, Johnstone, Selena, Peters, Victoria, Oram, Karen, Howe, Emma, Whiteley, Jane, Tunnacliffe, Gareth J, Veal
Publikováno v:
Pediatric Blood & Cancer
Background While the majority of childhood cancer clinical trials are treatment related, additional optional research investigations may be carried out that do not directly impact on treatment. It is essential that these studies are conducted ethical
Publikováno v:
European Journal of Cancer. 41:2280-2287
We assessed response to immunisation with trivalent split virus influenza vaccine in children with non-leukaemic malignant disease. Children with solid tumours and lymphoma received one or two doses of influenza vaccine, according to current UK guide
Autor:
Ann Elsworth, Gareth J. Veal, Carol Beane, Julie Errington, Julia C. Chisholm, Alan V. Boddy, Fiona Waters, Heather P. McDowell, Michael Cole, Karen Howe, Juliet Hale, Adam Glaser, Yvonne Wright, Ross Pinkerton, Sue Hemsworth, Kathy Pritchard-Jones, Annie Parry, Gail Jenner, James Nicholson, Bernadette Brennan, Andrew D.J. Pearson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(16)
Purpose: Dactinomycin (actinomycin D) is an antitumor antibiotic used routinely to treat certain pediatric and adult cancers. Despite concerns over the incidence of toxicity, little is known about the pharmacology of dactinomycin. A study was done to
Autor:
Alex J Eustace, Brigid C. Browne, N. Barron, Norma O'Donovan, Karen Howe, John Crown, Sinead T Aherne, S. Souahli, Naomi Walsh
Publikováno v:
Annals of Oncology. 23:ix528
HER2 positive breast cancer accounts for approximately 25 % of all breast cancer cases. Trastuzumab, a humanised monoclonal antibody, is an approved established treatment for HER2 positive breast cancer; however, patients that initially respond frequ